Vascular calcifications are very common in dialysis patients and have been shown to be associated independently with outcome. However, all of these studies used prevalent patients on dialysis since many years. We investigated vascular calcifications in an inception cohort of dialysis patients and followed them for cardiovascular disease outcomes during an average observation period of 66 months. One hundred and fifty-four Caucasian dialysis patients were enrolled in one Austrian dialysis center. Standardized plain radiographs from the pelvis and calves were carried out in all patients at the start of dialysis therapy. Vascular calcifications were assessed by a single radiologist. At the start of renal replacement therapy, 67.5% of the patients showed vascular calcifications. During follow-up, 29.9% of patients suffered a cardiovascular event. An additive 'vascular risk score', constructed from the presence of vascular calcifications and/or previous cardiovascular events before the start of dialysis treatment, showed the strongest independent association with cardiovascular events in the Cox regression model adjusted for various risk factors. The presence of each of these two conditions was associated with a hazard ratio of 2.03 (95% confidence interval 1.19-3.46) and a hazard ratio twice as high if both conditions were present. In summary, vascular calcifications on plain X-rays of pelvis and calves are largely present in incident dialysis patients. A history of a cardiovascular event in the predialysis period together with vascular calcifications at the beginning of dialysis therapy is a more powerful predictor of a cardiovascular event than age, smoking, diabetes, or other traditional risk factors.
Vascular calcifications are very common in dialysis patients and have been shown to be associated independently with outcome. However, all of these studies used prevalent patients on dialysis since many years. We investigated vascular calcifications in an inception cohort of dialysis patients and followed them for cardiovascular disease outcomes during an average observation period of 66 months. One hundred and fifty-four Caucasian dialysis patients were enrolled in one Austrian dialysis center. Standardized plain radiographs from the pelvis and calves were carried out in all patients at the start of dialysis therapy. Vascular calcifications were assessed by a single radiologist. At the start of renal replacement therapy, 67.5% of the patients showed vascular calcifications. During follow-up, 29 .9% of patients suffered a cardiovascular event. An additive 'vascular risk score', constructed from the presence of vascular calcifications and/or previous cardiovascular events before the start of dialysis treatment, showed the strongest independent association with cardiovascular events in the Cox regression model adjusted for various risk factors. The presence of each of these two conditions was associated with a hazard ratio of 2.03 (95% confidence interval 1. 19-3.46 ) and a hazard ratio twice as high if both conditions were present. In summary, vascular calcifications on plain X-rays of pelvis and calves are largely present in incident dialysis patients. A history of a cardiovascular event in the predialysis period together with vascular calcifications at the beginning of dialysis therapy is a more powerful predictor of a cardiovascular event than age, smoking, diabetes, or other traditional risk factors. Evidence of vascular calcification is exceedingly more striking in chronic renal failure than in the general population. 1,2 A combination of two major pathologies is responsible for this phenomenon. Firstly, intimal calcification occurring in atherosclerotic lesions, [3] [4] [5] and secondly, medial calcification, well-and long known as Mönckeberg sclerosis. 6 The precise etiology, however, is still unclear. Emerging evidence indicates that vascular calcification is an active cell-mediated process that is parallel to skeletal mineralization. 6 Advanced age, long time dialysis treatment, and diabetes are main risk factors. 7 Several mechanisms are believed to contribute to this burden: the chronic inflammatory state, 8 the deranged mineral metabolism, in particular elevated phosphate levels, 9, 10 as well as the widely used calcium-based phosphate binders. 11 Recent Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend plain X-rays for an assessment of vascular calcification. 12 Radiographs are universally available, cheap, and easy to perform. Vascular calcification has been shown to be associated with cardiovascular events in dialysis patients. [13] [14] [15] However, these studies were all carried out in long-term prevalent dialysis populations, which makes those studies susceptible to survival or onset-confounding bias. We therefore investigated vascular calcifications in an inception cohort of dialysis patients using plain X-rays of pelvis and calves.
One further aspect is allowed for in this paper: almost half of our patients underwent kidney transplantation during follow-up. For statistical analysis, however, this is associated with substantial bias, as health status and cardiovascular risk of patients undergoing renal transplantation (RTX) substantially differ from those remaining on dialysis. 16 Instead of censoring (or non-censoring) of observation period of patients undergoing RTX, we used a time-dependent covariate to account for this kind of difference.
RESULTS
At the start of dialysis therapy, 104 out of 154 patients (67.5%) showed radiologically visible calcifications. During the observation period of on average 66746 months, 46 patients (29.9%) suffered a cardiovascular event as listed in Table 1 . Thirteen of these 46 patients suffered a further cardiovascular event during the further observation period.
However, only the first event was considered for the analysis. Seventy patients underwent kidney transplantation, and two of them underwent two transplantations. From the 83 patients who died, 41% of these deaths were of cardiovascular reasons (myocardial infarction, heart failure, sudden death and ischemic as well as hemorrhagic stroke) and 59% of noncardiovascular reasons (mainly infections and therapy withdrawals and other reasons).
Univariate analysis
Univariate comparison of baseline characteristics between patients with and without cardiovascular events during follow-up is provided in Table 2 . Thirty-eight of the 46 patients (82.6%) who suffered a cardiovascular event during follow-up showed vascular calcifications at baseline compared to 61.1% of patients without an event (P ¼ 0.009). Similarly, the frequency of a history of previous cardiovascular events before the start of dialysis treatment was significantly higher (23.9 vs 9.3%, P ¼ 0.015). The composite variable 'vascular risk score' defined by these two variables showed the most pronounced differences between the two groups (P ¼ 0.004). Other significant variables in univariate analysis included diabetes (P ¼ 0.027) and ever-smoking (P ¼ 0.031).
The unadjusted Cox regression analysis revealed that all three variables -the presence of vascular calcifications, the history of a previous cardiovascular event, and each step in the combined vascular risk score -were associated with a more than threefold risk for a cardiovascular event during follow-up (first part of Table 3 ). Kaplan-Meier survival curves demonstrated significant differences in cumulative event-free survival between patients with and without previous cardiovascular events (Figure 1a ), with and without vascular calcifications at the time of enrollment (Figure 1b ), and the three groups of the vascular risk score (Figure 1c ). The latter suggests that the survival probability decreased linearly from those patients who had neither calcifications nor a positive cardiovascular history to those having one of both conditions to those having both conditions at baseline (Po0.0001; log-rank overall test).
Adjusted Cox regression analysis
Finally, the adjusted Cox regression analysis found the vascular risk score to have the strongest association with cardiovascular events besides age, smoking and diabetes mellitus (additive model in Table 3 ). The hazard ratio of about two indicates a twofold risk increase in case of the presence of either vascular calcifications or a positive history of cardiovascular events before the start of dialysis treatment The presence (coded as 1) or absence (coded as 0) of vascular calcifications and for previous cardiovascular events before the start of dialysis treatment was used to build a 'vascular risk score'. If a patient had none of both conditions, the score was 0, in case of one of both conditions, the score was 1, and in case of both conditions, this score was 2. and a hazard ratio of about four if both conditions were present in comparison to patients free of both. Alternative modeling without using this vascular risk score showed that each of these two conditions on its own was associated with a twofold increased risk with borderline significance (data not shown). Furthermore, we included an interaction term between vascular calcifications and a positive history of cardiovascular events before the start of dialysis treatment into the model that turned out to be not significant (see interaction model in Table 3 ). This makes an effect modification unlikely and favors an additive effect of the two variables, which is considered in the vascular risk score of the additive model.
DISCUSSION

Vascular calcification and cardiovascular events
This study demonstrates a strong and independent association of the vascular risk score (constructed by the presence of vascular calcifications and a history of cardiovascular events before dialysis enrollment) with future cardiovascular events. We investigated an inception cohort of dialysis patients during a mean follow-up period of 66 months. Especially the presence of both conditions was associated with a fourfold increased risk.
Our study clearly demonstrates that vascular calcifications are already present in more than two-thirds of the patients when renal replacement therapy is started. This is in line with a recent study in diabetic patients who demonstrated that these vascular changes develop already in earlier stages of chronic renal failure 17 and progress rapidly during dialysis treatment. Our results extend these findings to patients with other causes of kidney disease and furthermore underline vascular calcifications as an informative marker for future cardiovascular events, especially when present in patients with a history of a cardiovascular event.
A few other studies up to now addressed vascular calcifications assessed with plain radiographs in end-stage renal disease (ESRD) patients and its association with outcome. Blacher et al. 13 studied 110 long-term hemodialysis patients and used a combination of plain radiographs and vascular ultrasound to assess both intimal and medial vascular calcification in four vascular regions. An increase of one step in the four-grade score was associated with more than threefold higher cardiovascular mortality. The same research group 14 distinguished medial from intimal calcifications by the means of plain X-rays in 202 long-term hemodialysis patients. The authors were even able to prove the contribution of medial calcification to all-cause and cardiovascular mortality, albeit it was noted that outcome was worst for patients with a mixed pattern of calcification. Adragao et al. 15 noted similar results in a group of 123 hemodialysis patients.
In our inception cohort of dialysis patients, we were not able to find such strong correlations based on vascular calcifications alone. This might be explained by the fact that all of the above-mentioned studies followed prevalent cohorts of dialysis patients undergoing maintenance dialysis for a long time (average 81, 89, and 47 months) and that vascular The presence (coded as 1) or absence (coded as 0) of vascular calcifications and for previous cardiovascular events before the start of dialysis treatment was used to build a 'vascular risk score'. If a patient had none of both the score was zero, in case of one of both conditions the score was 1, in case of both conditions this score was 2.
calcifications are strongly associated with time already on dialysis treatment. 18 Further bias in prevalence studies can render interpretation of data difficult: 19 on the one hand, the patients with the highest comorbidity are the most likely to decease during the first years of treatment. On the other hand, the healthiest patients are more likely to undergo kidney transplantation. Therefore, prevalence studies with a long dialysis pretreatment are very likely to involve a highly selected patient population. Further, quite similarly, a bias may result as a consequence of onset-confounding. 19 Owing to the difference in dialysis pretreatment between patients, vascular calcification certainly is very heterogeneous. This might have led to an overestimation of the effect of vascular calcifications in earlier studies.
Recently, the results of a vascular calcification study in patients with renal transplantation became available. 20 Only 24.4% of incident transplanted patients showed vascular calcification on a posteroanterior plain radiography of the aortoiliacal region at the time of transplantation. This is in contrast to a frequency of more than 60% in our incident dialysis cohort which can be explained by the higher age of our patients (59 vs 43 years) and the selection of healthier patients suitable for transplantation in the above study. 20 Nevertheless, the authors demonstrated that even in this younger and healthier population, plain films can be a useful tool to predict cardiovascular and all-cause deaths. 20 
Limitations of the study
The observer-dependency is a general limitation of plain radiographs, which we tried to minimize by the fact that the scoring in all of our patients was performed by a single radiologist within a few days. A repeated scoring of the radiographs from a subsample of 20 patients several months later resulted in a 100% reproducibility. A further limitation is that the detection sensitivity yields only semi-quantitative data as discussed recently. 21 We classified calcifications as and without previous cardiovascular events before the enrollment into the study, (b) with and without vascular calcifications at the time of enrollment, and (c) the three groups of the vascular risk score (VRS). The VRS was built by summing the presence (coded as 1) or absence (coded as 0) of vascular calcifications and of previous cardiovascular events. If a patient had none of both conditions, the score was 0, in case of one of both conditions, the score was 1, and in case of both conditions, this score was 2. Numbers near the survival curves represent the number of patients at risk within each stratum at the times 0, 24, 48, 72, 96, 120, and 144 months of observation. absent or present, independent of location or extent. This makes us unable to discriminate between minor forms vs extensive calcifications. Unfortunately, diagnostic alternatives with similar cost and handling are not available. Certainly, new imaging methods such as Electron Beam Computer Tomography (EBCT) or newer forms of spiral computed tomography 18, 22, 23 have promised more sensitive measurements of tissue calcification, but have their own disadvantages, like high costs or higher exposure to radiation. [24] [25] [26] Finally, it will be necessary to validate the association of the vascular risk score with cardiovascular outcome in an independent study population. As our study group included only Caucasian patients, a replication study in other ethnicities will have to be performed.
Conclusion
Recent KDOQI guidelines recommended plain X-rays for the assessment of vascular calcification in ESRD patients. In this study, we were able to demonstrate a clinically highly interesting association of a vascular risk score with cardiovascular outcomes in an inception cohort of dialysis patients with a long-term follow-up.
MATERIALS AND METHODS Patients
We enrolled 155 Caucasian dialysis patients in an Austrian dialysis center (Feldkirch) for an investigation of vascular calcifications. 27 Enrollment started in 1990 and ended by the middle of 1997. Two patients were already recruited before 1990 as part of a pilot project. To be included into the analysis of the data, a patient had to survive dialysis for at least 3 months. A complete follow-up for 154 patients is available until April 2004. Baseline characteristics are given in Table 4 .
Radiological procedures
Standardized plain radiographs from the pelvis and calves were carried out in all patients at the start of dialysis therapy as described recently. 27 The prevalence of vascular calcifications was assessed by a single radiologist blinded to the clinical and laboratory data. Calcifications were counted as present if in any of these vessels either plaque-like (patchy) and/or circumferential contiguous calcifications were noted. For investigation of the intraobserver coefficient of variation, radiographs of 20 patients were reevaluated at least half a year following the first evaluation. All of these samples were correctly reclassified.
Risk factor evaluation
Diagnosis of hypertension and diabetes were based on several measurements of blood pressure and fasting blood glucose according to standard guidelines at the time of enrollment, or established treatment with antihypertensive and antidiabetic drugs. A full medical history was available for all patients. Smoking history (ever vs never) and previous cardiovascular events were selfreported or evaluated in the medical records. Previous cardiovascular events included a history of myocardial infarction, coronary artery bypass graft, percutaneous transluminal angioplasty, coronary stenosis 450%, and ischemic stroke. The presence (coded as 1) or absence (coded as 0) of vascular calcifications and for previous cardiovascular events before the start of dialysis therapy was used to build a 'vascular risk score' . If a patient had none of both conditions, the score was 0, in case of one of both conditions, the score was 1, and in case of both conditions, this score was 2. The prevalence of clinical and biochemical risk factors at the time of enrollment did not differ when we stratified patients into three groups of dialysis vintage (before 1993, 1993-1994, and after 1994) .
Laboratory procedures
Baseline values of all measured parameters were obtained from ethylenediaminetetraacetic acid plasma taken after a 12-h overnight fast before dialysis. Lipoprotein(a) quantification was performed using a double-antibody enzyme-linked immunosorbent assay as described in detail. 28 Lipids, lipoproteins, and apolipoproteins were measured as described previously. 27 Serum phosphorus levels and the calcium-phosphorus product were determined each month using the Hitachi 717 autoanalyzer (Roche, Mannheim, Germany). These levels are provided as time-averaged levels from the first year of dialysis treatment, to decrease intraindividual variability. Plasma intact parathyroid hormone was measured using a commercially available two-site immunoradiometric assay (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA).
Outcomes and censoring
All patients were followed prospectively until April 2004. One patient was lost to follow-up. The main outcome was a fatal or nonfatal cardiovascular event following the initiation of dialysis treatment. This included the following stringent criteria: definite myocardial infarction, coronary artery bypass graft, percutaneous transluminal angioplasty, stenosis of a coronary artery 450% diagnosed by angiography, ischemic stroke, established clinical diagnosis of a transient ischemic attack, and occlusion of a carotid vessel or carotid endarterectomy. Only the first event during the observation period was considered. The presence (coded as 1) or absence (coded as 0) of vascular calcifications and for previous cardiovascular events before the start of dialysis treatment was used to build a 'vascular risk score'. If a patient had none of both conditions, the score was 0, in case of one of both conditions, the score was 1, and in case of both conditions, this score was 2. 
Statistical procedures
Comparisons of continuous variables between patients with and without events during follow-up were performed using the unpaired t-test or the non-parametric Mann-Whitney U-test in case of nonnormally distributed variables. Categorical variables were compared using Pearson's w 2 test or Fisher's exact test. Kaplan-Meier survival curves were used to describe the cumulative incidence of cardiovascular event-free survival over time and the log-rank test was used to test for differences among the investigated groups. Unadjusted and adjusted Cox proportional hazards models were used to identify baseline risk factors for future cardiovascular events. The measure of association was the hazards ratio accompanied by the corresponding 95% confidence interval. A stepwise variable selection procedure included all variables at Po0.10 and excluded those at P40. 15 . The observation period of patients undergoing renal transplantation was not censored, but the treatment modality entered into the adjusted Cox regression model as a time-dependent covariate. Renal replacement modality, at a given time, was coded and entered in the models as either 0 or 1 (functioning transplant or dialysis, respectively). 29 This method even allows to model repeated kidney transplantations during the observation period without censoring. In case the graft lasted less than 90 days, transplantation was ignored in this time-dependent covariate. Death from a noncardiovascular event was considered as a censoring event. Variables entered into the adjusted Cox regression hazards models were those with a P-value o0.20 in the unadjusted Cox regression analysis as well as the time-dependent variable 'ESRD treatment modality' and sex. The analyses were carried out with SPSS for Windows (version 12.0.1) and SAS for Windows (version 9.1.3).
